Cellectar Biosciences Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Cellectar Biosciences, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.00
Cost of Revenue0.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.00
Operating Expenses
Research & Development26.1427.2718.2717.5910.149.006.84
Selling, General & Administrative25.6411.6910.556.545.155.184.82
Operating Expenses51.7838.9628.8124.1315.2914.1811.66
Operating Income-51.78-38.96-28.81-24.13-15.29-14.18-11.66
Other Income/Expense
Interest Income1.210.390.150.000.010.000.00
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense7.263.79-3.19-0.01-0.19-0.04-1.61
Income
Income Before Tax-44.52-42.83-31.85-24.12-15.09-14.09-13.24
Income Tax Expense0.07-0.06-0.06-8.17-4.900.000.00
Net Income-44.58-42.77-31.79-24.12-15.09-14.09-13.24
Net Income - Continuous Operations-44.58-42.77-31.79-24.120.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-51.49-42.58-28.67-23.98-15.15-13.96-11.57
EBIT-44.52-42.83-28.81-24.13-15.29-14.09-11.66
Depreciation & Amortization0.290.190.150.150.14-0.130.00
Earnings Per Share
Basic EPS-37.00-3.00-121.00-4.00-229.00--5.00
Diluted EPS-42.00-3.00-121.00-8.00-229.00-18.00-5.00
Basic Shares Outstanding1.2212.220.245.550.070.772.96
Diluted Shares Outstanding1.2412.220.245.550.070.772.96